Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small-Molecule Protein Kinase Inhibitors and Their Effects on the Immune System: Implications for Cancer Treatment
Patrick A. Ott, Sylvia Adams
Immunotherapy (2011) Vol. 3, Iss. 2, pp. 213-227
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek, Francisco J. Cueto, Adriana M. Mujal, et al.
Nature reviews. Immunology (2019) Vol. 20, Iss. 1, pp. 7-24
Closed Access | Times Cited: 1973
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Jahan S. Khalili, Shujuan Liu, Tania Rodríguez-Cruz, et al.
Clinical Cancer Research (2012) Vol. 18, Iss. 19, pp. 5329-5340
Open Access | Times Cited: 286
CAR T-Cell Therapy in Hematological Malignancies
Theresa Haslauer, Richard Greil, Nadja Zaborsky, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8996-8996
Open Access | Times Cited: 131
Insights of 8-hydroxyquinolines: A novel target in medicinal chemistry
Rohini Gupta, Vijay Luxami, Kamaldeep Paul
Bioorganic Chemistry (2021) Vol. 108, pp. 104633-104633
Closed Access | Times Cited: 106
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer
Ruth J. Davis, Carter Van Waes, Clint Allen
Oral Oncology (2016) Vol. 58, pp. 59-70
Open Access | Times Cited: 129
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
Sathana Dushyanthen, Zhi L. Teo, Franco Caramia, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 105
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Margaret E. Gatti‐Mays, Jason M. Redman, Julie Collins, et al.
Human Vaccines & Immunotherapeutics (2017) Vol. 13, Iss. 11, pp. 2561-2574
Open Access | Times Cited: 102
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication
Gustavo Garcia, Arun Sharma, Arunachalam Ramaiah, et al.
Cell Reports (2021) Vol. 35, Iss. 1, pp. 108940-108940
Open Access | Times Cited: 101
Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers
Ellen Moore, Harrison Cash, Andria M. Caruso, et al.
Cancer Immunology Research (2016) Vol. 4, Iss. 7, pp. 611-620
Open Access | Times Cited: 93
The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer
Mohammed H. Abu-Alghayth, Farhan R. Khan, Tareg M. Belali, et al.
Pathology - Research and Practice (2024) Vol. 255, pp. 155180-155180
Closed Access | Times Cited: 8
Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs
Stanford Schor, Shirit Einav
DNA and Cell Biology (2017) Vol. 37, Iss. 2, pp. 63-69
Open Access | Times Cited: 86
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights
Ping‐Pin Zheng, Jin Li, Johan M. Kros
Medicinal Research Reviews (2017) Vol. 38, Iss. 1, pp. 325-376
Open Access | Times Cited: 73
Inhibition of IRF5 hyperactivation protects from lupus onset and severity
Su Song, Saurav De, Victoria L. Nelson, et al.
Journal of Clinical Investigation (2020) Vol. 130, Iss. 12, pp. 6700-6717
Open Access | Times Cited: 68
MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88
Cristina Benito‐Villalvilla, Cristina Cirauqui, Carmen M. Diez‐Rivero, et al.
Mucosal Immunology (2016) Vol. 10, Iss. 4, pp. 924-935
Open Access | Times Cited: 61
Influenza Vaccines: Successes and Continuing Challenges
Tanja Becker, Husni Elbahesh, Leslie A. Reperant, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. Supplement_4, pp. S405-S419
Open Access | Times Cited: 53
Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue
David J. Monsma, Noel R. Monks, David Cherba, et al.
Journal of Translational Medicine (2012) Vol. 10, Iss. 1
Open Access | Times Cited: 60
The functional role of p38 MAPK pathway in malignant brain tumors
Nathália Grave, Thamiris Becker Scheffel, Fernanda Fernandes Cruz, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 24
mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer
Harrison Cash, Sujay Shah, Ellen Moore, et al.
Oncotarget (2015) Vol. 6, Iss. 34, pp. 36400-36417
Open Access | Times Cited: 48
Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia
Ian W. Flinn, Mohamad Cherry, Michael B. Maris, et al.
American Journal of Hematology (2019) Vol. 94, Iss. 12, pp. 1325-1334
Open Access | Times Cited: 37
Targeting Crucial Host Factors of SARS-CoV-2
Anil Mathew Tharappel, Subodh Kumar Samrat, Zhong Li, et al.
ACS Infectious Diseases (2020) Vol. 6, Iss. 11, pp. 2844-2865
Open Access | Times Cited: 35
Advances in immunotherapy for MMR proficient colorectal cancer
Hazel Lote, Naureen Starling, Rille Pihlak, et al.
Cancer Treatment Reviews (2022) Vol. 111, pp. 102480-102480
Open Access | Times Cited: 21
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
Sophia Stock, Anna-Kristina Kluever, Stefan Endres, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 307-307
Open Access | Times Cited: 19
CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?
María C. Ramello, Eric B. Haura, Daniel Abate‐Daga
Pharmacological Research (2017) Vol. 129, pp. 194-203
Open Access | Times Cited: 36
Osmium–Tellurium Nanozymes for Pentamodal Combinatorial Cancer Therapy
Seounghun Kang, Yeong‐Gyu Gil, Gyeonghye Yim, et al.
ACS Applied Materials & Interfaces (2021) Vol. 13, Iss. 37, pp. 44124-44135
Closed Access | Times Cited: 25
Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy
Ashley Knights, Jitka Fučíková, Anupama Pasam, et al.
Cancer Immunology Immunotherapy (2012) Vol. 62, Iss. 2, pp. 321-335
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top